Medherant’s testosterone TEPI Patch has been well-tolerated and has demonstrated excellent wearability.

Medherant is planning for further clinical evaluation of the testosterone TEPI Patch that is being developed for treatment of hypoactive sexual desire disorder, or distressing low libido, in post-menopausal women. Medherant is also considering clinical studies to investigate other potential benefits of testosterone therapy.

“This signals a significant step towards developing a licensed product for addressing post-menopausal women's health needs,” says Karolina Afors, Medherant’s Medical Director. “We look forward to advancing our research and contributing meaningfully to the field of women's health.”

About Medherant

Medherant’s lead development product is a testosterone patch for post-menopausal women utilising Medherant’s novel transdermal TEPI Patch proprietary technology. Despite the recommendation contained in the NICE Menopause Guidelines and Global Consensus Position Statement on the Use of Testosterone Therapy for Women there is no approved testosterone product for women.

The company was founded by University of Warwick’s Professor of Polymer Chemistry, Professor David Haddleton and is developing the novel transdermal TEPI Patch technology which can create patches that have more favourable wear characteristics for patients, with good adhesion and are non-irritant to patients whilst not leaving adhesive residue on patients’ skin.

In addition to developing its own products, Medherant collaborates with pharmaceutical companies in developing transdermal patch products for already approved drugs.
TEPI Patch is a registered trademark of Medherant Limited.